Delanghe J R, Duprez D A, De Buyzere M L, Bergez B M, Claeys L R, Leroux-Roels G G, Clement D L
Department of Clinical Chemistry, University Hospital, Gent, Belgium.
J Cardiovasc Risk. 1995 Apr;2(2):131-6.
Many cases of refractory hypertension cannot be attributed to specific identifiable factors. Haptoglobin polymorphism has been suggested as a candidate genetic marker in essential hypertension. The aim of this study was to investigate the distribution of haptoglobin types in patients with refractory hypertension.
Haptoglobin polymorphism was studied in 383 patients with non-refractory and 62 patients with refractory hypertension. Haptoglobin was typed using starch gel electrophoresis of haemoglobin-supplemented serum.
In the group of patients with refractory hypertension, the relative allele frequency of haptoglobin 1 (0.266) was lower than in the group with non-refractory hypertension (0.385: P < or = 0.05). The relative frequency of haptoglobin 2-2 was 39% in the non-refractory compared with 56% in the refractory group (P < or = 0.05). In the latter group, the relative frequency of haptoglobin 2-2 was highest (75%) in patients requiring medication with four classes of drug.
Hypertension patients with the haptoglobin 2-2 phenotype are at higher risk of developing refractory hypertension than those with other haptoglobin phenotypes.
许多难治性高血压病例无法归因于特定的可识别因素。有人提出触珠蛋白多态性是原发性高血压的候选遗传标记。本研究的目的是调查难治性高血压患者中触珠蛋白类型的分布情况。
对383例非难治性高血压患者和62例难治性高血压患者进行了触珠蛋白多态性研究。采用补充血红蛋白的血清淀粉凝胶电泳法对触珠蛋白进行分型。
在难治性高血压患者组中，触珠蛋白1的相对等位基因频率（0.266）低于非难治性高血压患者组（0.385：P≤0.05）。非难治性组中触珠蛋白2-2的相对频率为39%，而难治性组为56%（P≤0.05）。在后一组中，需要使用四类药物治疗的患者中触珠蛋白2-2的相对频率最高（75%）。
与其他触珠蛋白表型的高血压患者相比，具有触珠蛋白2-2表型的高血压患者发生难治性高血压的风险更高。
